Eagle's Eye View: Your Weekly CV Update From ACC.org (Week of September 13)

This week's View summarizes articles about whether there are differences in daily symptom scores on statin, placebo, and no treatment in participants who had abandoned statins; the safety and immunogenicity of heterologous schedules with different coronavirus disease 2019 (COVID-19) vaccines; and the effectiveness of inhaled budesonide in reducing recovery time and rates of COVID-19-related hospital admission or death in people at high risk of an adverse outcome.

Clinical Topics: Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Dyslipidemia, Prevention, Nonstatins, Novel Agents, Statins

Keywords: EaglesEyeView, Adenoviridae, Anti-Asthmatic Agents, Atorvastatin, Body Mass Index, Bronchodilator Agents, Budesonide, Comorbidity, Coronavirus, COVID-19, COVID-19 Vaccines, ACC COVID-19 Podcast, Enzyme-Linked Immunosorbent Assay, Fatigue, Fibric Acids, Genetic Vectors, Hematologic Tests, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Immunity, Immunoglobulin G, Muscle Cramp, Myalgia, Nocebo Effect, Patient Admission, Primary Prevention, Primary Health Care, Risk, RNA, Messenger, SARS-CoV-2, Secondary Prevention, Smartphone, Vaccination, Viral Vaccines, Dyslipidemias

< Back to Listings